tisagenlecleucel

February 8, 2019

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended that Kymriah (tisagenlecleucel) be offered to patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL) through the Cancer Drugs Fund. Specifically, this Novartis-developed therapy ... Read more

September 25, 2018

NICE Rejects Kymriah for England’s NHS to Treat Aggressive DLBCL

News

Kymriah (tisagenlecleucel), developed by Novartis, has not been recommended as a treatment for adults with aggressive diffuse large B-cell lymphoma (DLBCL) for England’s National Health Service (NHS). The National Institute for Health ... Read more

May 3, 2018

FDA Approves Kymriah for Relapsed or Refractory Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory large B-cell lymphoma, Novartis announced. Specifically, the approval of intravenous Kymriah suspension is ... Read more

March 29, 2018March 29, 2018

CAR T-cell Therapies Deemed Cost-effective for B-cell Cancers in New Report

News

Treatment with chimeric antigen receptor (CAR) T-cell therapies in B-cell cancers, like certain types of lymphoma and leukemia, is associated with an increase in quality-adjusted and overall survival compared to ... Read more

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

November 2, 2017

Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL

News

Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more

August 31, 2017September 1, 2017

FDA Approves First-Ever CAR T-Cell Therapy, Kymriah, for Young B-Cell ALL Patients

News

In what is described as a historical decision, the U.S. Food and Drug Administration (FDA) has approved the first gene therapy-based cancer treatment in the United States. The FDA approved Novartis’ ... Read more

June 15, 2017

37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear

News

Thirty-seven percent of patients with a difficult-to-treat lymphoma had their cancer disappear after receiving Novartis’ CTL019 (tisagenlecleucel), according to an interim analysis of Phase 2 clinical trial results. Other patients achieved ... Read more